Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Itacitinib to Prevent Graft Versus Host Disease

NCT04127721 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT04127721
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04127721 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Itacitinib to Prevent Graft Versus Host Disease
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Withdrawn
Start date
September 22, 2020
Completion date
September 22, 2020
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

allogeneic stem cell transplant recipient, hematologic and lymphocytic disorder, hematopoietic and lymphoid cell neoplasm